Results 21 to 30 of about 2,498 (139)
Cabergoline and the risk of valvular lesions in endocrine disease. [PDF]
, 2008 peer reviewedAIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.
Livadariu, E. +7 more
core +1 more source
Ожирение и метаболизм, 2015 Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed
Galina Afanas'evna Melnichenko +3 more
doaj +1 more source
Cabergoline treatment in acromegaly: pros [PDF]
, 2014 Cabergoline is an ergot-derived dopamine D2 receptor agonist which may be effective for the medical management of acromegaly. Its efficacy in reducing growth hormone and IGF-I levels, as well as its antiproliferative and pro-apoptotic effects on ...
Ramos-Levi, A +3 more
core +1 more source
Saudi Pharmaceutical Journal, 2023 Background: There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on ...
Pouria Rahmanian-Devin +3 more
doaj +1 more source
Cabergoline Treatment in Invasive Giant Prolactinoma
, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Sadeem Alsubaie, Mussa H. Almalki
core +1 more source
Giant prolactinoma case with side effects due to cabergoline
, 2020 Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas. Cabergoline is preferred first.
Hüseyin Dursun +3 more
core +1 more source
Middle East Fertility Society Journal, 2011 Background: Prophylactic use of dopamine agonist has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). Objective: To compare cabergoline with cabergoline plus I.V albumin or I.V albumin alone in prevention of ...
Badeea S. Soliman
doaj +1 more source
De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline
Clinical Medicine Insights: Case Reports, 2023 Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de novo psychiatric symptoms during dopamine agonist therapy is low.
Chayma Belhadj Slimane +4 more
doaj +1 more source
, 2014 Hyperthyroidism is an important inducing factor in patients with atrial fibrillation, and may trigger heart failure. Thyrotropin (thyroid stimulating hormone, TSH)-secreting pituitary tumors are rare causes of hyperthyroidism.
黃天祥 ;張恬君 +1 more
core +1 more source
Effectiveness of Cabergoline therapy in hyperprolactinemic infertility [PDF]
, 2019 Background: Hyperprolactinemia may be associated with ovulatory dysfunction and resultant subfertility. Hyperprolactinemia affects the pulsatile release of GnRH, which in turn impairs the secretion of FSH and LH. It may also affect the endocrine activity
Pitale, Devdatt Laxman
core +1 more source